Human Anti-CD40 Recombinant Antibody (clone 21.4.1) (CAT#: HPAB-1834-FY)

Figure 1 CH1-hinge basis of agonistically inactive IgG3 and superior IgG2.

Representative FACS profile showing the percentage of OT-I cells (CD45.1+TCRVα2+) among CD8+ T cells in human CD40/FcγR-transgenic mice treated and analyzed together with control or anti-human CD40 antibodies of indicated clones (Clones 21.4.1 and 3.1.1 have been described in Patent No.:US 7,338,660; Clone 21.4.1 in the IgG2 form is also known as CP-870,893) and constant domains (30 μg per mouse).

Liu, X., Zhao, Y., Shi, H., Zhang, Y., Yin, X., Liu, M., ... & Li, F. (2019). Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature communications, 10(1), 1-15.

Figure 2 CH1-hinge basis of agonistically inactive IgG3 and superior IgG2.

Representative quantification showing the percentage of OT-I cells (CD45.1+TCRVα2+) among CD8+ T cells in human CD40/FcγR-transgenic mice treated and analyzed together with control or anti-human CD40 antibodies of indicated clones (Clones 21.4.1, Clone 21.4.1 in the IgG2 form is also known as CP-870,893) and constant domains (30 μg per mouse).

Liu, X., Zhao, Y., Shi, H., Zhang, Y., Yin, X., Liu, M., ... & Li, F. (2019). Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature communications, 10(1), 1-15.

Figure 3 Shows a dose-response curve that illustrates the ability of an anti-CD40 antibody of the invention (21.4.1) to enhance IL-12p40 production by human dendritic cells.

Figure 4 Shows a dose-response curve that illustrates the ability of an anti-CD40 antibody of the invention (21.4.1) to enhance IL-12p70 production by human dendritic cells.

Figure 5 Shows a tumor growth inhibition curve that illustrates the reduced growth of CD40 positive Daudi tumors in SCID-beige mice treated with an anti-CD40 antibody of the invention (21.4.1).

Figure 6 Shows a Western blot analysis of anti-CD40 agonist antibodies to reduced (R) and non-reduced (NR) human CD40.